BACKGROUND: To date the therapy for non-small cell lung cancer (NSCLC) is associated with severe side effects, frustrating outcomes, and does not consider different tumor characteristics. The RNA-interference (RNAi) pathway represents a potential new approach to treat NSCLC. With small interfering ribonucleic acids (siRNAs), it is possible to reduce the expression of proliferation-dependent proteins in tumor cells, leading to their apoptosis. We propose that siRNAs could be adapted to the tumor type and may cause fewer side effects than current therapy. METHODS: Four NSCLC cell lines were cultured under standard conditions and transfected with three different concentrations of siRNAs targeted against the hypoxia-inducible factors 1α and 2α (HIF1α and HIF2α) and signal transducer and activator of transcription 3 (STAT3). The expression was observed by quantitative real-time polymerase chain reaction and western blots. For the analysis of cell growth three days after transfection, the cell number was detected using a CASY cell counter system. RESULTS: The results of the silencing of the analyzed factors differ in each cell line. Cell growth was significantly reduced in all cell lines after transfection with HIF1α- and STAT3-siRNA. The silencing of HIF2α resulted in a significant effect on cell growth in squamous, and large-cell lung cancer. CONCLUSIONS: This study shows that the knockdown and viability to siRNA transfection differ in each tumor type according to the used siRNA. This implies that the tumor types differ among themselves and should be treated differently. Therefore, the authors suggest a possible approach to a more personalized treatment of NSCLC.
BACKGROUND: To date the therapy for non-small cell lung cancer (NSCLC) is associated with severe side effects, frustrating outcomes, and does not consider different tumor characteristics. The RNA-interference (RNAi) pathway represents a potential new approach to treat NSCLC. With small interfering ribonucleic acids (siRNAs), it is possible to reduce the expression of proliferation-dependent proteins in tumor cells, leading to their apoptosis. We propose that siRNAs could be adapted to the tumor type and may cause fewer side effects than current therapy. METHODS: Four NSCLC cell lines were cultured under standard conditions and transfected with three different concentrations of siRNAs targeted against the hypoxia-inducible factors 1α and 2α (HIF1α and HIF2α) and signal transducer and activator of transcription 3 (STAT3). The expression was observed by quantitative real-time polymerase chain reaction and western blots. For the analysis of cell growth three days after transfection, the cell number was detected using a CASY cell counter system. RESULTS: The results of the silencing of the analyzed factors differ in each cell line. Cell growth was significantly reduced in all cell lines after transfection with HIF1α- and STAT3-siRNA. The silencing of HIF2α resulted in a significant effect on cell growth in squamous, and large-cell lung cancer. CONCLUSIONS: This study shows that the knockdown and viability to siRNA transfection differ in each tumor type according to the used siRNA. This implies that the tumor types differ among themselves and should be treated differently. Therefore, the authors suggest a possible approach to a more personalized treatment of NSCLC.
Authors: K Takeda; K Noguchi; W Shi; T Tanaka; M Matsumoto; N Yoshida; T Kishimoto; S Akira Journal: Proc Natl Acad Sci U S A Date: 1997-04-15 Impact factor: 11.205
Authors: Barbara Chiavarina; Diana Whitaker-Menezes; Gemma Migneco; Ubaldo E Martinez-Outschoorn; Stephanos Pavlides; Anthony Howell; Herbert B Tanowitz; Mathew C Casimiro; Chenguang Wang; Richard G Pestell; Philip Grieshaber; Jaime Caro; Federica Sotgia; Michael P Lisanti Journal: Cell Cycle Date: 2010-09-04 Impact factor: 4.534
Authors: F Kamlah; B G Eul; S Li; N Lang; L M Marsh; W Seeger; F Grimminger; F Rose; J Hänze Journal: Cancer Gene Ther Date: 2008-09-26 Impact factor: 5.987
Authors: Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas Journal: Nature Date: 2010-03-21 Impact factor: 49.962
Authors: James V Alvarez; Heidi Greulich; William R Sellers; Matthew Meyerson; David A Frank Journal: Cancer Res Date: 2006-03-15 Impact factor: 12.701
Authors: Sara C Hanna; Bhavani Krishnan; Sean T Bailey; Stergios J Moschos; Pei-Fen Kuan; Takeshi Shimamura; Lukas D Osborne; Marni B Siegel; Lyn M Duncan; E Tim O'Brien; Richard Superfine; C Ryan Miller; M Celeste Simon; Kwok-Kin Wong; William Y Kim Journal: J Clin Invest Date: 2013-04-08 Impact factor: 14.808
Authors: Andrea Nolte; Stefan Aufderklamm; Katrin Scheu; Tobias Walker; Olivia König; Miriam Böttcher; Jan Niederlaender; Christian Schwentner; Christian Schlensak; Arnulf Stenzl; Hans Peter Wendel Journal: Nucleic Acid Ther Date: 2013-01-11 Impact factor: 5.486